STAT, April 19, 2023: An FDA proposal to study whether opioids are effective as a chronic pain treatment is facing major resistance from addiction and pain care experts who are not paid by industry. We told STAT that the proposed clinical trial is unethical because it will provide no new information and would make some patients more dependent on opioids.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
For Canadian Patients, Therapeutic Psychedelics Beset by Red Tape
Undark, March 8, 2023: Undark article reviews the red tape in Canada vs. U.S. for access to psychedelics for cancer patients and other depressed patients. In this news article, we explain FDA expanded access program, which tends to make access easier if companies agree to help patients.
Read More »The Obesity Revolution
STAT, March 5, 2023: Novo Nordisk makes a popular weight loss drug and they want doctors to prescribe it. They have paid for materials to teach medical students that weight loss drugs are effective, and we tell STAT that med students are a captive audience and shouldn’t be taught by a company that sells the drugs that they are learning about. That doesn’t just push the envelope, it shreds it.
Read More »FDA could widen path for OTC birth control, statins
Roll Call, March 2, 2023: Roll Call explains that FDA proposes broadening access to some common medications that currently require a doctor’s prescription. FDA suggests replacing prescriptions with a short quiz for over-the-counter access. We ask if patients will be careful enough to safely use these products.
Read More »Lawmakers, advocates press for diversity in clinical trials
National Journal, February 15, 2023: NCHR joins lawmakers and other advocates in urging FDA and NIH to improve diversity in race/ethnicity, age, and sex in clinical trials as a way to improve medical care for everyone. So far, enforcement is lacking.
Read More »